In a recent column in Health Affairs, Precision’s Jason Shafrin and Mark Linthicum address how value assessment frameworks are leading to more patient-centered formularies.
Phil Cyr and Larry Blandford offer their experience and insights on developing health economic models for gene and cellular therapies. (more…)
Precision’s All Access is our bimonthly newsletter with original content written by our payer experts for market access leaders. (more…)
In part 2 of their Guest Commentary series, Precision’s Todd Edgar, Alex Grosvenor, and Kellie Rademacher highlight the takeaways of the NOR-SWITCH trial and how the EU’s view of biosimilars as therapeutic alternatives is influencing US policy. (more…)
Precision’s Ross Maclean and Jeroen Jansen encourage biopharma and medical device industries to embrace the developments around value assessment and to take a leading role in improving the transparency of cost-effectiveness evaluations. (more…)
In a feature in Pharma Live, Precision’s Jeremy Schafer and Maureen Hennessy predict that the projected growth in healthcare spend is creating an inevitable marketplace shift from volume to value. (more…)
In Part 1 of a two-part series, Todd Edgar, Alex Grosvenor, and Kellie Rademacher discuss EU biosimilar policies and their impact on the US approach, with a focus on payer coverage. (more…)
In an original article appearing in Journal of Clinical Pathways, Ashwin Athri, SVP Precision Promotional Effectiveness, discusses how variations in health systems influence oncology practices. (more…)
The February issue of All Access, Precision’s free newsletter featuring articles by former payers written specifically for market access leaders, is now available. (more…)
In a new commentary for Pharmaceutical Market Europe, Precision for Value’s Austin Speier, VP, Emerging Technology, examines the promise and advantages of integrating digital biomarkers into precision medicine. (more…)